PMID- 33012745
OWN - NLM
STAT- MEDLINE
DCOM- 20211101
LR  - 20211101
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 68
IP  - 2
DP  - 2021 Feb 28
TI  - Distinct clinical features and prognosis between persistent and temporary thyroid 
      dysfunctions by immune-checkpoint inhibitors.
PG  - 231-241
LID - 10.1507/endocrj.EJ20-0371 [doi]
AB  - Immune-related adverse events in the thyroid glands (thyroid irAEs) during 
      treatment with immune-checkpoint inhibitors (ICIs) are most frequent endocrine 
      irAE. Thyroid irAE can be divided into that requiring continuous therapy for 
      thyroid dysfunction (P-THY), and that requiring only temporal treatment (T-THY). 
      However, predictive factors for those differential outcomes are unknown, and 
      susceptibility of human leukocyte antigen (HLA) to thyroid irAE has never been 
      investigated. This study aimed to elucidate clinical courses and prognosis of 
      P-THY in comparison with T-THY in the aspect of thyroid immunity and HLA. 
      Patients with P-THY (n = 15) that required L-T4 supplemental therapy for 
      hypothyroidism for more than 3 months, and patients with T-THY who required no 
      therapy or therapy within 1 month were enrolled in the study. Lower-value of TSH, 
      higher-value of FT4, and lower value of TSH/FT4 were thought to be predictive 
      markers to estimate P-THY. In addition, anti-thyroglobulin antibody (TgAb) levels 
      were significantly higher in patients with P-THY than those in patients with 
      T-THY. HLA-DPA1*01:03 and HLA-DPB1*02:01 allele, and their haplotype frequencies 
      were significantly higher in patients with P-THY than those in controls. P-THY 
      had better survival rate than T-THY. Pre-existing thyroid autoimmunity, the 
      extent of thyroid dysfunction, and predisposing HLA were associated with the 
      differential course of thyroid irAEs. It was suggested that thyroid function 
      tests, TgAb, and HLA typing tests are useful for prediction of clinical course in 
      thyroid irAEs.
FAU - Inaba, Hidefumi
AU  - Inaba H
AD  - The First Department of Medicine, Wakayama Medical University, Wakayama, Japan.
FAU - Ariyasu, Hiroyuki
AU  - Ariyasu H
AD  - The First Department of Medicine, Wakayama Medical University, Wakayama, Japan.
FAU - Iwakura, Hiroshi
AU  - Iwakura H
AD  - The First Department of Medicine, Wakayama Medical University, Wakayama, Japan.
FAU - Kurimoto, Chiaki
AU  - Kurimoto C
AD  - The First Department of Medicine, Wakayama Medical University, Wakayama, Japan.
FAU - Takeshima, Ken
AU  - Takeshima K
AD  - The First Department of Medicine, Wakayama Medical University, Wakayama, Japan.
FAU - Morita, Shuhei
AU  - Morita S
AD  - The First Department of Medicine, Wakayama Medical University, Wakayama, Japan.
FAU - Furuta, Hiroto
AU  - Furuta H
AD  - The First Department of Medicine, Wakayama Medical University, Wakayama, Japan.
FAU - Hotomi, Muneki
AU  - Hotomi M
AD  - Department of Otolaryngology-Head and Neck Surgery, Wakayama Medical University, 
      Wakayama, Japan.
FAU - Akamizu, Takashi
AU  - Akamizu T
AD  - The First Department of Medicine, Wakayama Medical University, Wakayama, Japan.
LA  - eng
PT  - Journal Article
DEP - 20201003
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Immunological/administration & dosage/*adverse effects
MH  - Female
MH  - Humans
MH  - Immune Checkpoint Inhibitors/administration & dosage/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*drug therapy
MH  - Prognosis
MH  - Thyroid Diseases/*chemically induced
MH  - Thyroid Gland/*drug effects/physiopathology
OTO - NOTNLM
OT  - Human leukocyte antigen
OT  - Immune-checkpoint inhibitors
OT  - Immune-related adverse events
OT  - Thyroid gland
EDAT- 2020/10/06 06:00
MHDA- 2021/11/03 06:00
CRDT- 2020/10/05 06:11
PHST- 2020/10/06 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2020/10/05 06:11 [entrez]
AID - 10.1507/endocrj.EJ20-0371 [doi]
PST - ppublish
SO  - Endocr J. 2021 Feb 28;68(2):231-241. doi: 10.1507/endocrj.EJ20-0371. Epub 2020 
      Oct 3.